Bedrocan Receives Additional License Capacity from Health Canada
TORONTO, Aug. 27, 2015 /CNW/ – Bedrocan Cannabis Corp. (TSXV: BED) (the “Company” or “Bedrocan”) announced today that it has received a license amendment from Health Canada allowing it to sell up to 2,000 kilograms of medical cannabis over the five and a half months ending on February 17, 2016, which is the end of the Company’s current license period. In addition, Bedrocan retains its license to sell up to 240 kilograms of cannabis from its second licensed facility. These sales can be sourced from imports into Canada from its Dutch partner and licensor Bedrocan Beheer BV, or from any other licensed producer.
As previously announced on August 24, 2015, Bedrocan’s Canadian production facility has been fully licensed by Health Canada, including all 34 production rooms, three dispensing rooms, the building’s two-floor, Level 9 security vault, and the ability to dispose of all cannabis production waste via composting. Bedrocan also has a second facility in the Greater Toronto Area, licensed by Health Canada, to process, dispense and sell medical cannabis.
“The license amendments received this week give us the scope we need to significantly expand our reach, both through expanding production and through accelerated marketing and medical education,” said Marc Wayne, President and CEO of Bedrocan. “Patients can be assured of a secure, uninterrupted supply of Bedrocan’s standardized, pharmaceutical-grade medical cannabis, grown in Canada.”
Bedrocan Cannabis Corp. is focused on clinical research, technologically-advanced, automated production processes, and innovative product development. Bedrocan Canada and its licensor Bedrocan Beheer BV (Netherlands) are the only companies in the world currently capable of producing standardized full-bud, pharmaceutical-grade medicinal cannabis.
On August 24, 2015, shareholders of Bedrocan Cannabis Corp. voted to approve a plan of arrangement (the “Arrangement”) involving the acquisition by Tweed Marijuana Inc. (TSXV: TWD) (“TMI”) of all of the issued and outstanding common shares of Bedrocan. The Arrangement remains subject to the satisfaction or waiver of a number of conditions which are specified in Bedrocan’s management information circular dated July 20, 2015. It is expected that the Arrangement will be completed on or about August 28, 2015. Upon closing of the Arrangement, Bedrocan will become a subsidiary of TMI. For further information, please refer to the press release of the Company dated June 24, 2015 available on SEDAR at www.sedar.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding the proposed Arrangement, anticipated timing for the closing of the Arrangement, operations of the combined entity, the ability of the combined entity to expand and capture market share. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance. All forward-looking information contained in this news release is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof. The closing of the proposed Arrangement is subject to a number of conditions, some of which are outside the control of the parties involved. If those closing conditions are not satisfied, the Arrangement may not occur. The combined entity may not be able to achieve the market growth and success anticipated by the parties. For a description of the risks associated with the business conducted by TMI, please refer to TMI’s final short-form prospectus dated March 10, 2015. The information circular delivered to shareholders of Bedrocan contains additional disclosure about TMI and the Arrangement, including the risk factors associated therewith. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Readers are cautioned not to put undue reliance on these forward looking statements.
SOURCE Bedrocan Cannabis Corp
The post Bedrocan Receives Additional License Capacity from Health Canada appeared first on MJI News.